Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

New research led by Department of Physiology, Anatomy & Genetics researcher Dr Kerstin Timm shows that a recently developed imaging technique can detect early metabolic changes in the heart caused by a commonly used chemotherapy drug, which is known to increase risk of heart failure in cancer survivors.

Illustration of a human heart

Chemotherapy has greatly improved cancer survival rates, especially in breast cancer patients. However, some chemotherapeutic drugs such as doxorubicin have side effects on the heart, and 5-10% of cancer survivors develop heart failure as a consequence of their cancer treatment. Unfortunately, it is not currently possible to predict which patient will suffer long-term heart problems due to their cancer therapy.

An imaging tool to screen patients regularly to check for early signs of toxicity on the heart is therefore desirable to detect any changes early and intervene with appropriate treatment. However, current clinical imaging is limited to detection of cardiac dysfunction, not prior toxic events. A recently developed imaging technique called “Hyperpolarized 13C Magnetic Resonance Imaging” allows us to assess real-time metabolic fluxes in vivo, and may therefore provide the ability to detect changes in mitochondrial metabolism and function in the doxorubicin treated heart. This technique has been pioneered in the UK in both the rodent and human heart by Professor Damian Tyler’s lab.  

The full story is available on the Department of Physiology, Anatomy & Genetics website

Similar stories

Alternating vaccines trial expands to include two additional vaccines

Clinical Trials Coronavirus COVID-19 General

Researchers running the Com-Cov study, launched in February to investigate alternating doses of the Oxford-AstraZeneca vaccine and the Pfizer vaccine, have today announced that the programme will be extended to include the Moderna and Novavax vaccines in a new study.

Oxford medical students launch flagship raffle in aid of NHS heroes and lifesaving medical equipment

General

Tingewick, a society formed of medical students from Oxford University, are hosting a virtual charity raffle. With over 70 amazing prizes, ranging from Truck festival tickets to restaurant vouchers to bags of books and even a bike, the raffle is an exciting way to celebrate lockdown lifting by supporting many wonderful Oxfordshire businesses whilst raising lots of money for charity.

Asthma drug budesonide shortens recovery time in non-hospitalised patients with COVID-19

Clinical Trials Coronavirus COVID-19 Research

Inhaled budesonide, a common corticosteroid, is the first widely available, inexpensive drug found to shorten recovery times in COVID-19 patients aged over 50 who are treated at home and in other community settings, reports the PRINCIPLE trial in 1,779 participants.

UK and EU regulators conclude benefits of vaccination continue to outweigh the risks

Coronavirus COVID-19 General

Today, the medical regulators in the UK and Europe have announced their conclusions from their reviews of very rare cases of unusual blood clots in people who have received the Oxford-AstraZeneca coronavirus vaccine.

Link between COVID-19 infection and subsequent mental health and neurological conditions found

Coronavirus COVID-19 General Research

One in three COVID-19 survivors received a neurological or psychiatric diagnosis within six months of infection with the SARS-CoV-2 virus, an observational study of more than 230,000 patient health records published in The Lancet Psychiatry journal estimates. The study looked at 14 neurological and mental health disorders.